Meghan Fitzgerald

CIK 1349297 · EVP, Strategy & Health Policy · last filed 2026-09-18

Meghan Fitzgerald is an EVP, Strategy & Health Policy who has filed 42 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for ROIV, was dated Sep 18, 2026. Across all open-market trades the lifetime net is −$7.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.7M across reported positions. 20 SEC filings were submitted jointly with Roivant Sciences Ltd. 5 Form 144 notices of planned sales are also on file; the latest, for ROIV on Sep 15, 2026, lists the filer as an officer.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$10.68M
Companies
6
Total Filings
42
Lifetime Open-Market Net
-$6.95M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

THC price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
1461 ANHINGA PT
NAPLES, FL 34105
Related Filers
Roivant Sciences Ltd. — 20 joint filings, latest 2026-09-18
CARDINAL HEALTH INC — 4 joint filings, latest 2015-11-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ROIV Director 41,162 $39.17 $1.61M -$3.27M 13 2026-09-18
THC Director 17,087 $263.24 $4.50M -$3.68M 15 2026-05-28
Roivant Sciences Ltd. (ROIVW) Delisted Director 1,152 $2.75 $3.2K $0 2 2023-07-06
CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted Director — $8.37 — $0 3 2018-06-18
CAH EVP, Strategy & Health Policy 16,760 $272.81 $4.57M $0 3 2015-11-17
VION PHARMACEUTICALS INC (VION) Delisted VP and Chief Business Officer 55,500 — — $0 1 2007-03-14

Recent Filings

42 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2026-09-18 ROIV Grant (A) +5,054 $0 EDGAR
2026-09-17 ROIV Sell (S)10b5-1
Plan adopted Mar 30, 2026
−5,112 -$203.2K EDGAR
2026-09-15 ROIV Notice (144)
Officer · Planned Sep 15, 2026 · 10b5-1 plan
Sold: Form 4 filed Sep 17, 2026
−5,112 -$209.7K EDGAR
2026-09-14 ROIV Tax (F) −1,743 -$71.4K EDGAR
2026-09-10 ROIV Mixed10b5-1
Plan adopted Mar 30, 2026
— -$622.0K EDGAR
2026-09-08 ROIV Notice (144)
Director · Planned Sep 8, 2026 · 10b5-1 plan
Sold: Form 4 filed Sep 10, 2026
−20,000 -$698.6K EDGAR
2026-07-02 ROIV Mixed10b5-1 — -$261.0K EDGAR
2026-06-30 ROIV Notice (144)
Director · Planned Jun 30, 2026 · 10b5-1 plan
Sold: Form 4 filed Jul 2, 2026
−10,000 -$347.3K EDGAR
2026-05-28 THC Grant (A) — $0 EDGAR
2026-05-26 THC Mixed +840 -$85.7K EDGAR
Showing 1–10 of 42
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).